Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Brevard · SciRah

Researcher profile · Semantic Scholar

J. Brevard

Share profile

J. Brevard — researcher profile on SciRah

h-index: 13
Works: 31
Citations: 938

Most-cited papers

Connecting to Young Adults: An Online Social Network Survey of Beliefs and Attitudes Associated With Prescription Opioid Misuse Among College Students
S. Lord, J. Brevard, S. Budman
2011Substance Use & Misuse148 citations Open access
Semantic Scholar
MyStudentBody–Stress: An Online Stress Management Intervention for College Students
E. Chiauzzi, J. Brevard, C. Thurn, S. Decembrele +1 more
2008Journal of health communication130 citations
Semantic Scholar
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
S. de Botton, P. Fenaux, K. Yee, C. Récher +25 more
2023Blood Advances124 citations Open access
Semantic Scholar
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
J. Watts, M. Baer, Jay Yang, T. Prebet +24 more
2022The Lancet Haematology99 citations
Semantic Scholar
IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis.
D. Balak, M. V. van Doorn, R. Arbeit, R. Rijneveld +7 more
2017Clinical Immunology89 citations
Semantic Scholar
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial
M. I. de la Fuente, H. Colman, M. Rosenthal, B. Van Tine +14 more
2022Neuro-Oncology79 citations Open access
Semantic Scholar
Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials
C. Beysen, P. Schroeder, E. Wu, J. Brevard +10 more
2020Diabetes, obesity and metabolism47 citations Open access
Semantic Scholar
Teaching Adolescents About Changing Bodies: Randomized Controlled Trial of an Internet Puberty Education and Body Dissatisfaction Prevention Program
T. Cousineau, D. Franko, Meredith Trant, Diana Rancourt +3 more
2010Body image40 citations Open access
Semantic Scholar
Two-minute skin anesthesia through ultrasound pretreatment and iontophoretic delivery of a topical anesthetic: a feasibility study.
E. Spierings, J. Brevard, Nathaniel Katz
2008Pain medicine (Malden, Mass.)28 citations
Semantic Scholar
D1 agonist improved movement of parkinsonian nonhuman primates with limited dyskinesia side effects.
D. Young, M. Popiolek, Patrick E. Trapa, Kari R. Fonseca +3 more
2020ACS Chemical Neuroscience26 citations
Semantic Scholar
Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study
J. Watts, M. Baer, Jay Yang, T. Prebet +22 more
2019Blood25 citations Open access
Semantic Scholar
Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies
M. Patel, G. Garcia-Manero, R. Paquette, S. Dinner +9 more
2019Blood21 citations Open access
Semantic Scholar
Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine
J. Cortes, Eunice S. Wang, J. Watts, Sangmin Lee +15 more
2019Blood16 citations Open access
Semantic Scholar
Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia
Jordi Cortés, J. Esteve, A. Bajel, K. Yee +21 more
2021Blood12 citations Open access
Semantic Scholar
Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia
S. Thomas, W. Harb, J. Beck, Gabrail Nashat +14 more
201510 citations
Semantic Scholar
Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial
Jorge E. Cortes, P. Fenaux, K. Yee, C. Récher +15 more
2022Blood9 citations Open access
Semantic Scholar
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
Andreas Lundqvist, V. van Hoef, Xiao-Nan Zhang, E. Wennerberg +496 more
2016Journal for ImmunoTherapy of Cancer9 citations Open access
Semantic Scholar
Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease
A. Lal, R. Brown, T. Coates, T. Kalfa +5 more
2021Blood4 citations Open access
Semantic Scholar
An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)
K. Wood, J. Geib, E. Wu, Jason Berlin +6 more
20204 citations Open access
Semantic Scholar
PS1051 FT-2102, AN IDH1 M INHIBITOR, INDUCES MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) TREATED IN PHASE 1 DOSE ESCALATION AND EXPANSION STUDY
S. de Botton, J. Watts, M. Baer, Jay Yang +15 more
2019HemaSphere4 citations Open access
Semantic Scholar
AB0629 Design of A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of The Toll-like Receptor Antagonist IMO-8400 in Patients with Dermatomyositis
Patrick Gordon, R. Cooper, H. Chinoy, D. Isenberg +7 more
20164 citations
Semantic Scholar
Abstract 5652: Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase I/II study in patients with anti-PD-1 refractory metastatic melanoma
C. Haymaker, M. Uemura, R. Murthy, M. James +20 more
20173 citations
Semantic Scholar
S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
A. Lal, C. Brown, T. Coates, T. Kalfa +5 more
2022HemaSphere2 citations Open access
Semantic Scholar
PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
A. Lal, R. Brown, T. Coates, T. Kalfa +5 more
2022HemaSphere2 citations Open access
Semantic Scholar
Author response for "Inhibition of fatty acid synthase with FT ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non‐alcoholic fatty liver disease: results from two early phase randomized trials"
C. Beysen, P. Schroeder, E. Wu, J. Brevard +10 more
20202 citations Open access
Semantic Scholar
ACTR-52. PHASE 1 STUDY OF FT-2102, AN INHIBITOR OF MUTANT IDH1, IN PATIENTS WITH RELAPSED/REFRACTORY IDH1 MUTANT GLIOMAS: PRELIMINARY SAFETY AND CLINICAL ACTIVITY
M. I. de la Fuente, H. Colman, M. Rosenthal, B. Van Tine +10 more
2019Neuro-Oncology2 citations Open access
Semantic Scholar
Design Considerations for Clinical Trials Using the Cutaneous Dermatomyositis Disease Area and Severity Index as a Primary Endpoint
J. Brevard, M. Hurtt, J. Horobin, O. Polyanskaya +3 more
20171 citations
Semantic Scholar
PF269 FT-2102, AN IDH1 M INHIBITOR, COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS): RESULTS FROM A PHASE 1 STUDY
J. Cortes, J. Watts, M. Baer, T. Prebet +17 more
2019HemaSphere0 citations Open access
Semantic Scholar
The histamine skin prick test: An analysis of the method for use in clinical trials.
J. Brevard, Mary Anne Elder, G. Berman, Ye Tan +4 more
2016Annals of Allergy, Asthma & Immunology0 citations
Semantic Scholar
(896): The NAVIPPRO system: New data on the feasibility of real-time, product-specific, prescription opioid abuse surveillance
S. Butler, S. Budman, A. Villapiano, J. Brevard +3 more
20070 citations Open access
Semantic Scholar
4: Improving young adolescents’ puberty knowledge: A randomized controlled trial
T. Cousineau, D. Franko, Meredith Watt, J. Brevard +1 more
20070 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Sweeney×9
Invite
J. Sweeney — researcher profile on SciRah
A. Wei×7
Invite
A. Wei — researcher profile on SciRah
J. Watts×7
Invite
J. Watts — researcher profile on SciRah
S. Forsyth×7
Invite
S. Forsyth — researcher profile on SciRah

×6

Invite

S. de Botton — researcher profile on SciRah

P. Montesinos×6

Invite

P. Montesinos — researcher profile on SciRah

Invite

B. Jonas — researcher profile on SciRah

Invite

Jay Yang — researcher profile on SciRah

Invite

S. Dinner — researcher profile on SciRah

Hesham Mohamed×6

Invite

Hesham Mohamed — researcher profile on SciRah

Invite

C. Récher — researcher profile on SciRah

Invite

J. Cortes — researcher profile on SciRah